The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.
Settlement with Dr. Reddy's Laboratories shields key drugs NEXLETOL and NEXLIZET from generic competition until 2040, boosting investor confidence.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Governor Newsom's signature on AB30 is expected to expand the ethanol market by over 600 million gallons annually.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
The networking specialist saw trading volume spike more than 50 times its daily average following the announcement.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
Sale was executed under a pre-planned 10b5-1 trading arrangement as the AI chipmaker's valuation continues to soar.